KARINA TREVINO: Open Payments
NPI 1760718811 · MISSION, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,167 in 90 payments from 25 companies in 2025. Trend: 2023 $1,575 · 2024 $1,621 · 2025 $2,167
Food & beverage: $2,167
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $358 |
| Novo Nordisk Inc | 17 | $354 |
| Dexcom, Inc. | 8 | $304 |
| ABBVIE INC. | 14 | $182 |
| Lilly USA, LLC | 8 | $179 |
| Otsuka America Pharmaceutical, Inc. | 4 | $105 |
| PFIZER INC. | 5 | $101 |
| Verona Pharma, Inc. | 4 | $99 |
| Merck Sharp & Dohme LLC | 4 | $88 |
| GlaxoSmithKline, LLC. | 4 | $69 |
Products named: Dexcom G6 Transmitter, AIRSUPRA, BREZTRI, Ozempic, REXULTI, ELIQUIS, Ohtuvayre, VERQUVO.
Industry payments across TX — which companies pay providers there.
